DEA Proposes to Strip Exemption Status from Inactive Butalbital Products Under Controlled Substances Act

What this means for your practice

For most telehealth platforms, medspas, dental offices, and chiropractic practices, this proposed rule is a narrow administrative housekeeping action — not a sweeping policy change. However, any prescriber or practice that has historically relied on a specific butalbital combination product should verify that the product's NDC number remains active before assuming it retains exempt status. If a product your practice references appears on DEA's Table of Exempted Prescription Products but has an inactive NDC, it could lose its exemption once this rule is finalized, triggering full controlled substance scheduling requirements and the associated DEA registration, recordkeeping, and prescribing obligations. Practices should also be aware that the public comment window closes June 25, 2026, providing a brief opportunity to submit feedback if your formulary or patient population would be materially affected.

DEA Moves to Clean Up Inactive Butalbital Exemptions — What Healthcare Operators Need to Know

The Drug Enforcement Administration (DEA) published a Notice of Proposed Rulemaking (NPRM) on May 26, 2026, in the Federal Register proposing to remove certain butalbital-containing prescription products from its Table of Exempted Prescription Products. The action is limited to products whose National Drug Codes (NDCs) are inactive — meaning the products are no longer commercially available and/or the company that originally applied for the exemption no longer exists.

Background: What Is the Table of Exempted Prescription Products?

Under the Controlled Substances Act (CSA), the Attorney General — through delegated authority to the DEA Administrator — has the power to exempt certain nonnarcotic controlled substance combinations from the full scheduling requirements of the CSA. To qualify, a product must:

1. Be approved for prescription use, and 2. Contain one or more other active ingredients not listed in any controlled substance schedule, combined in quantities or proportions sufficient to vitiate the potential for abuse.

Products meeting these criteria are placed on DEA's Table of Exempted Prescription Products, which effectively relieves prescribers, pharmacies, and distributors from some of the administrative and regulatory burdens that would otherwise apply under the CSA.

Butalbital — a barbiturate used primarily in combination headache medications — has historically appeared in products on this exemption table when formulated with non-scheduled ingredients such as acetaminophen and caffeine.

What the Proposed Rule Actually Does

DEA's proposed rule under 21 CFR Part 1308 (Docket No. DEA-1664, RIN 1117-ZA08) does not reschedule butalbital broadly. Instead, it proposes a targeted cleanup of the exemption table:

• Products being targeted: Only butalbital combination products with inactive NDC numbers — those no longer manufactured, distributed, or backed by an existing applicant company.
• Products NOT affected: Any butalbital combination product with an active NDC number retains its exempt status under this proposal.
• Net regulatory effect: If finalized, the removed products would no longer be considered exempt prescription products, meaning they would be subject to the full controlled substance regulatory framework under the CSA.

The DEA's legal authority to revoke an exemption follows the same procedural pathway used to grant one — a Federal Register NPRM, a public comment period, and consideration of any objections before a final rule is issued.

Why This Matters: Inactive NDCs and Regulatory Ghost Products

The practical concern this rule addresses is a regulatory cleanliness issue: products that technically remain on an exemption list but are no longer commercially active create ambiguity. If a product is delisted from its NDC registry — because the manufacturer ceased operations or the product was discontinued — but remains on the DEA exemption table, it creates potential confusion about what regulatory obligations apply if a similar or generic product enters the market under a new NDC.

By removing inactive NDC products from the exemption table, DEA is ensuring that any new or reintroduced formulation of a butalbital product would need to independently qualify for exempt status — it cannot simply inherit the exemption of a discontinued predecessor product.

Practical Implications for Healthcare and Telehealth Operators

For most practices, the immediate operational impact is low. This is a targeted administrative action, not a broad rescheduling of butalbital or butalbital combinations.

However, the following practice types and scenarios warrant attention:

Telehealth platforms with headache or migraine treatment protocols: If your clinical protocols reference specific butalbital combination products — particularly older or less commonly dispensed formulations — confirm with your dispensing pharmacy partners that the product's NDC is currently active. An inactive NDC product losing its exemption would mean that product, if somehow still being dispensed, would trigger full CSA compliance obligations.

Compounding pharmacies and medspas: Compounded preparations are generally not covered by NDC-based exemptions. Practices relying on compounded butalbital formulations should already be treating those products under standard controlled substance frameworks.

Dental practices: Butalbital combination products have occasionally appeared in dental pain management contexts. Dental operators should verify that any butalbital product in their formulary or recommended to patients carries an active NDC.

Chiropractic practices: Chiropractors generally do not prescribe controlled substances, but practices operating under integrated care models or referring patients to affiliated prescribers should be aware of this regulatory update.

Comment Deadline: June 25, 2026

The DEA is accepting public comments on this proposed rule through June 25, 2026. Comments must be submitted electronically via regulations.gov referencing Docket No. DEA-1664, or mailed to DEA's Springfield, Virginia address.

Practices or organizations with formulary-specific concerns about named products should review the full docket and consider submitting a comment if affected operations can be documented. Confidential business information may be submitted under the dual-copy procedure described in the NPRM.

Key Takeaways

• Scope is narrow: Only inactive-NDC butalbital products are affected; active-NDC products are explicitly excluded.
• Not a rescheduling action: This is an exemption table cleanup, not a change to butalbital's scheduling status under the CSA.
• Verify your formulary: Any practice that prescribes or recommends butalbital combinations should confirm the relevant product's NDC is active.
• Comment window is short: If your practice is materially affected, comments must be submitted by June 25, 2026.
• Ongoing monitoring required: Once finalized, this rule will alter the regulatory status of the named products — compliance programs should be updated to reflect the change.

Source: DEA — Proposed Rule: Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products · 2026-05-26